BioCircuit Technologies

Executive Summary

BioCircuit Technologies is a private medical device company based in San Diego, focused on tissue repair and neuromodulation. Its flagship product, Nerve Tape®, is the first sutureless device for repairing transected peripheral nerves, addressing a significant unmet need in microsurgery. By simplifying nerve coaptation, Nerve Tape reduces operative time, eliminates needle-related trauma, and improves outcomes. The company has a strong intellectual property portfolio and is positioned to capture share in the $2B+ peripheral nerve repair market, which is driven by rising trauma and surgical volumes. With early commercial traction and positive surgeon feedback, BioCircuit is scaling manufacturing and pursuing broader indications. The platform technology also holds promise for other soft tissue applications and neuromodulation, offering multiple pipeline opportunities beyond the initial nerve repair focus. The management team combines deep expertise in neurosurgery, biomaterials, and medical device commercialization, positioning the company for sustained growth. Despite being at an early commercial stage, Nerve Tape's differentiated value proposition and clear regulatory path support a favorable risk-reward profile for investors seeking exposure to innovative surgical technologies.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for expanded Nerve Tape indications (e.g., larger diameter nerves)70% success
• Q4 2026National distribution partnership with a major orthopedic or neurosurgery device company60% success
• Q2 2026Publication of pivotal clinical data demonstrating superiority over standard microsutures80% success